{"id":46479,"date":"2022-07-22T15:02:16","date_gmt":"2022-07-22T13:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/"},"modified":"2022-07-22T15:02:16","modified_gmt":"2022-07-22T13:02:16","slug":"zymeworks-reports-inducement-grant-to-new-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/","title":{"rendered":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer"},"content":{"rendered":"
\n

VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the \u201cNYSE Rule\u201d), an equity inducement award to Dr. Paul Moore, Zymeworks\u2019 new Chief Scientific Officer.\n<\/p>\n

<\/a><\/p>\n

\nIn accordance with the NYSE Rule, Zymeworks approved the grant of the following equity award to Dr. Moore as a material inducement to Dr. Moore entering into employment with Zymeworks: effective as of the date his employment with Zymeworks began, a stock option to purchase 200,000 of the company\u2019s common shares (the \u201cOptions\u201d). The Options have an exercise price per share of $5.82, which equals the closing price of the company\u2019s common shares on July 18, 2022, and have a maximum term of 10 years. Dr. Moore\u2019s employment with the company began on July 18, 2022 (the \u201cStart Date\u201d).\n<\/p>\n

\nThe Options will vest over a four-year period as follows: (i) 1\/4 of the Options will vest on the one-year anniversary of the Start Date and (ii) 1\/36 of the remaining Options will vest on the last day of each month following the one-year anniversary of the Start Date until all of the Options have vested, subject to Dr. Moore\u2019s continued service. In addition, if there is a change of control and within 12 months following such change of control his employment is terminated by the company without cause, 100% of the unvested Options will become fully vested as of the termination of his employment.\n<\/p>\n

\nThe Options were granted outside of the company\u2019s Amended and Restated Stock Option and Equity Compensation Plan (the \u201cCurrent Plan\u201d) under the Zymeworks Inc. Inducement Stock Option and Equity Compensation Plan and related option agreement, but will be subject to terms and conditions generally consistent with those in the Current Plan other than with respect to such other terms and conditions intended to comply with the NYSE inducement award exception.\n<\/p>\n

\nAbout Zymeworks Inc.<\/b>\n<\/p>\n

\nZymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks\u2019 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks\u2019 lead clinical candidate, zanidatamab, is a novel Azymetric\u2122 HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks\u2019 second clinical candidate, ZW49, is a novel bispecific HER2\u2011targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks\u2019 proprietary ZymeLink\u2122 linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com<\/a>. For additional information about Zymeworks, visit www.zymeworks.com<\/a> and follow @ZymeworksInc<\/a> on Twitter.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Inquiries:<\/b>
Jack Spinks
\n
(604) 678-1388
\n
ir@zymeworks.com<\/a><\/p>\n

Media Inquiries:<\/b>
Diana Papove
\n
(604) 678-1388
\n
media@zymeworks.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the \u201cNYSE Rule\u201d), an equity inducement award to Dr. Paul Moore, Zymeworks\u2019 new Chief Scientific Officer. In accordance with the NYSE Rule, Zymeworks approved … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46479","6":"format-standard","7":"category-industry"},"yoast_head":"\nZymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the \u201cNYSE Rule\u201d), an equity inducement award to Dr. Paul Moore, Zymeworks\u2019 new Chief Scientific Officer. In accordance with the NYSE Rule, Zymeworks approved ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-22T13:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Zymeworks Reports Inducement Grant to New Chief Scientific Officer\",\"datePublished\":\"2022-07-22T13:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/\"},\"wordCount\":514,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005011\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/\",\"name\":\"Zymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005011\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"datePublished\":\"2022-07-22T13:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005011\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005011\\\/en\\\/183056\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Reports Inducement Grant to New Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend","og_description":"VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the \u201cNYSE Rule\u201d), an equity inducement award to Dr. Paul Moore, Zymeworks\u2019 new Chief Scientific Officer. In accordance with the NYSE Rule, Zymeworks approved ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-22T13:02:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer","datePublished":"2022-07-22T13:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/"},"wordCount":514,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/","url":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/","name":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg","datePublished":"2022-07-22T13:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220722005011\/en\/183056\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/zymeworks-reports-inducement-grant-to-new-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Reports Inducement Grant to New Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46479"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46479\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}